Rivaroxaban Superior to Enoxaparin in Non-Major Orthopaedic Surgery for Prevention of Major VTE .
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery
N Engl J Med. 2020 May 14;382(20):1916-1925.Three thousand six hundred and four patients scheduled for a non-major lower limb surgery were randomized to receive oral rivaroxaban or subcutaneous enoxaparin for the prevention of major venous thromboembolic events. The primary outcome of interest was major venous thromboembolism, which was a composite of the incidence of symptomatic distal or proximal deep vein thrombosis, pulmonary embolism and venous thromboembolism. Secondary outcomes of interest included the incidence of major bleeding, non-major clinically relevant bleeding, thrombocytopenia, and mortality. Outcomes were assessed by telephone 30 days after the end of treatment, which lasted until the end of immobilization. Results of the study demonstrated that the incidence of major venous thromboembolism to be significantly lower in the rivaroxaban group compared to the enoxaparin group. No significant differences in all secondary outcomes were observed.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
